Cleavable esters for nanocarrier-based cancer therapy
AssigneeThe Children's Hospital of Philadelphia
InventorsIvan Alferiev, Michael Chorny, Garrett M. Brodeur
Life of this patent
Estimating the term…
Abstract
A co-drug according to Formula (I) or Formula (II) is provided, R—X—NH—CO—CO—OR1 (I) R—X—CO—O—CH2—CO—OR1 (II) wherein R is a tocol moiety, a tocol analog moiety, or a capsaicinoid moiety; X is a direct bond or a linking group; and OR1 is the residue of an anticancer or antirestenotic agent bearing at least one hydroxyl group by which the CO—OR1 ester linkage is formed. Nanoparticles that include the abovementioned co-drug are also provided, as well as a method of treating a cancer patient that includes administering an effective amount of the co-drug or nanoparticles.
Claims12
A co-drug according to Formula (I) or Formula (II),
- R—X—NH—CO—CO—OR1 (I)
- R—X—CO—O—CH2—CO—OR1 (II)
- wherein:
- R is a tocol moiety, a tocol analog moiety, or a capsaicinoid moiety;
- X is a direct bond or [O(CH2)2]n, where n is an integer from 1 to 1000;
- and
- OR1 is the residue of an anticancer or antirestenotic agent bearing at least one hydroxyl group by which the CO—OR1 ester linkage is formed.
A co-drug R—O—CO(CH2)2—CO—O—CH2—CO—OR1 in which R is an α-tocopherol moiety and OR1 is an SN-22 residue.
A co-drug R—O(CH2)2—NH—CO—CO—OR1 in which R is an α-tocopherol moiety and OR1 is an SN-22 residue.
Dependencies are inferred from the claim text.